MedTrace Logo

Psychometric Validation of the Camouflaging Autistic Traits Questionnaire

NCT05989685 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 622

Last updated 2025-03-12

No results posted yet for this study

Summary

For many affected individuals, despite impairment and distress, autism spectrum disorder (ASD) is recognized and diagnosed late, in school age, adolescence, or even in adulthood, which could be due, among other things, to the use of compensatory strategies such as so-called "camouflaging" by the respective individual. In order to better investigate and quantify these adaptive and compensatory strategies of individuals with autism, the Camouflaging Autistic Traits Questionnaire (CAT-Q) has recently been developed and validated in the English-speaking world. The CAT-Q is designed to assess the extent of camouflaging behavior, in which autistic individuals consciously or unconsciously attempt to conceal or attenuate their autistic traits in order to better adapt to social situations. So far, however, there is no German-language questionnaire that can be used to validly assess camouflaging. The aim of the planned research project is to psychometrically validate the CAT-Q in German-speaking adolescents aged 13-21 years. The validation of the CAT-Q represents an important basis for further research on the construct camouflaging and can subsequently contribute to an improvement of diagnostics as well as support the development of individual treatment approaches.

Conditions

Sponsors & Collaborators

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Johannes Boettcher, Dr. · Universitätsklinikum Hamburg-Eppendorf

  • Sarah Hohmann, Prof. Dr. · Universitätsklinikum Hamburg-Eppendorf

  • Carola Bindt, Dr. · Universitätsklinikum Hamburg-Eppendorf

  • Benno Schimmelmann, Prof. Dr. · Universitäre Psychiatrische Dienste Bern

Eligibility

Min Age
13 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2025-08-31
Completion
2025-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05989685 on ClinicalTrials.gov